Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib in NF2 and Progressive Vestibular Schwannomas
NCT04283669Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2020
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crizotinib in neurofibromatosis type 2 (NF2), vestibular schwannoma (VS), sponsored by University of Alabama at Birmingham. Started Feb 2020; status: completed.
02
Drugs
crizotinib
03
Conditions
neurofibromatosis type 2 (NF2)vestibular schwannoma (VS)
Beyond the preview
Go deeper on NCT04283669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04283669.